# pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium

> **NCT01785290** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 1800 (actual)

## Conditions studied

- Delirium

## Interventions

- **DRUG:** Haloperidol 1 mg/q8h
- **DRUG:** Haloperidol 2 mg/q8h
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01785290
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2020-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785290, "pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01785290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*